August 4, 2011 PSW Staff |
|
 | |  | |  | |  | |  | |  | |  | |  | |  |
Full article access includes Buy, Sell & Stop-Loss conditions along with a no nonsense trading strategy and risk analysis. Also, access our actionable, unbiased portfolio, exclusive articles and more. Enter your Email Below to get Started for Free |
|
Safely Boost Your Portfolio Are you sick and tired of wading through all the garbage out there in the world of low priced stocks, the biased newsletters, the bogus twitter alerts and all the other noise? Access Our Acclaimed Portfolio and Members Only Reports Now Absolutely Free for Two Full Weeks |
Delivered to Your Inbox Each and Every Week (We Do Not Spam) |
only on those issues trading under a dollar, or even under a quarter or less. This is a function of the shear percentage of OTCBB and Pink Sheet stocks that trade below $1 compared to other price ranges, as well as the very reason traders are drawn to over the counter stocks in the first place. Nevertheless, there are plenty of OTCBB and Pink Sheet stocks trading above a dollar that are worth a look, especially when we consider the increase in quality in relation to the still high volatility and exponential percentage opportunities. We have to be just as careful when screening these equities as we are with the lower priced ones as plenty of scams will still be present. Your major screening priority should be to watch out for stocks that have recently undergone a reverse split forcing an inorganic rise into the one digit range. This type of situation will be more prevalent on the Pink Sheets as compared to the OTCBB, and the outcome is almost always a quick decent back down into the penny or sub- penny spectrum. Also keep in mind that legitimate unlisted stocks above a dollar will generally see lighter trading activity, but are also less likely to be in the midst of a and have interesting business models. These stocks should still be treated with the same amount of skepticism as their sub-dollar counterparts, but may offer a bit more peace of mind and some more solid growth potential. ETAK (Elephant Talk Communications Inc.) Elephant Talk Communications, Inc. provides business software and services to telecommunications and financial services industries in the Netherlands and internationally. The company's recent acquisition of ValidSoft gives them a unique position in the relatively infantile mobile payments security arena. Mobile payments are expected to rise from $240 billion to $670 billion in 2015, and so far, the level of security is no where near what it is for traditional online payments. The company recently announced that it has come to an agreement with Zain Saudi Arabia to deliver and manage mobile services for mobile brands in the Kingdom of Saudi Arabia. Revenues have been on the decline for ETAK recently, but gross profit has been on the rise, and net loss has been shrinking dramatically. The company's financials do not currently include the ValidSoft numbers. ETAK has over $4.3 million in cash and less than a half million dollars in debt. Shareholder equity is positive and has been growing over the last three quarters, and the company expects to be cash-flow positive by the end of the year. TTNP (Titan Pharmaceuticals Inc.) Titan Pharmaceuticals, Inc. develops therapeutics primarily for the treatment of central nervous system disorders. Titans potential blockbuster drug Probuphine, which is for the treatment of Opioid addiction, has experienced positive Phase III clinical trial results. The company resolved issues with the FDA regarding confirmation that subjects were indeed opiate users and were not just saying that they were. This resolution allowed the FDA to allow the study to proceed, and not cause a stock plummeting delay that was previously feared. Titan has given up substantial future royalties on the drug in order raise cash, but still looks to gain some significant revenues if it makes it to market. The financing has so far been relatively non-dilutive, and TTNP currently sits with around 60 million shares outstanding. Given the companies current position, speculation of being a take over target may continue to grow, along with the stock price. LFVN (Lifevantage Corporation) LifeVantage Corporation operates as science-based nutraceutical company that engages in helping people reach their health and wellness goals. The company has recently vamped up selling and marketing initiatives for its suite of products. Revenues have been climbing dramatically, from $4 million in 2009, to $11 million in 2010. So far in 2011, revenues were close to $10 million in the first quarter alone, and the company is giving guidance of close to $40 million for all of 2011. LifeVantage is a growing its cash coffers which now total over $4 million, and they have been shrinking their long term debt, now at $9 million. LFVN has about 80 million shares outstanding. The company has barely been cash flow positive for several years, but during the most recent quarter, they generated over $1 million. IMUC (ImmunoCellular Therapeutics, Ltd.) ImmunoCellular Therapeutics, Ltd. focuses on developing and commercializing therapeutics to fight cancer using the immune system. IMUC is very small with only 28 million shares outstanding, and an enterprise value of just $47 million. The company’s main product, ICT-107, is a vaccine to treat a very aggressive brain cancer that currently has limited treatment options. Results from a Phase I study were somewhat promising, as it more than doubled the survival times of patients compared to the current standard of care. The company recently launched Phase II trials. IMUC is a development stage company, and currently has about $11 million in cash and no debt. OBJE (Obscene Jeans Corp.) Obscene Jeans Corporation designs, develops, manufactures, markets, wholesales, distributes, and sells a woman’s line of Obscene Brand jeans. The company is focused on being a leader with respect to the latest Milan, Paris and New York runway fashions. OBJE has a tiny amount of shares outstanding, 13 million, and an even tinier float of just 4 million shares. The company is still in development stage and does not have any revenues to report yet. The company has a tiny balance sheet as well, with just $84,000 in assets and just $333,000 in liabilities. The jeans look to gain attention when they debut this month in Las Vegas at WWDMAGIC, a premier fashion showcase. The jeans have also been featured in several publications, one touting them as “the future of denim”. Also, Obscene Jeans recently announced plans to acquire activewear clothing company We Are Yoga. Unlike most penny stock websites, PSW provides completely UNBIASED analysis. In other words, we do not accept compensation in any form from companies or third parties to promote their stocks. This means that you get analysis and opinion on Small and Micro Cap stocks that is untainted and completely transparent. This is in stark contrast to 99% of all “Free” penny stock reports and “services”. Sign up below to get our free, unbiased, weekly newsletter delivered to your inbox, or follow us on Facebook, Twitter and LinkedIn. You will also receive a free, no strings attached two-week trial offer to access our premium service. Here, you'll get full article access, member exclusive articles and access to our real-time, unbiased portfolio that is up more than 8000% since 2003, as well as our weekly members only portfolio update. |